Under construction – not a live service

Skip to content

Frontlight Research

Institution

Tongji Hospital

Wuhan, ChinahealthcareWebsite

228running trials
53closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
NCT06136507· Phase 3· Source
Not yet recruiting
A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
NCT07917923· Early phase 1· Source
Not yet recruiting
ACT201 Injection in Participants With Chronic Hepatitis B (CHB) on Nucleos(t)Ide Analog Therapy - Phase Ib
NCT07929805· Phase 1· Source
Not yet recruiting
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606· Phase 3· Source
Not yet recruiting
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
NCT07781150· Phase 2· Source
Not yet recruiting
A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Relapsing/Refractory Multiple Sclerosis
NCT07748637· Early phase 1· Source
Recruiting
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT07575672· Phase 3· Source
Not yet recruiting
AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
NCT07732504· Source
Not yet recruiting
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
NCT07784101· Phase 3· Source
Not yet recruiting
A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
NCT07843862· Phase 2· Source
Not yet recruiting
AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
NCT07729618· Source
Recruiting
Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07871110· Phase 2· Source
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Source
Not yet recruiting
A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
NCT07632235· Phase 1/2· Source
Not yet recruiting
Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer
NCT07865611· Phase 2· Source
Recruiting
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
NCT07412262· Phase 2· Source
Recruiting
A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis
NCT07827716· Phase 2· Source
Not yet recruiting
Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD
NCT07665359· Source
Not yet recruiting
Neoadjuvant PD-1 Inhibitor Plus SOX Chemotherapy With or Without Short-Course Radiotherapy for Locally Advanced Upper Gastric or GEJ Adenocarcinoma
NCT07674342· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Source
Active, not recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity
NCT07559136· Phase 1· Source
Recruiting
A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer
NCT07619235· Phase 4· Source
Recruiting
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
NCT07663253· Source
Not yet recruiting
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
NCT07537946· Phase 3· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Source
Recruiting
Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA)
NCT07594314· Phase 2/3· Source
Recruiting
Minocycline After Successful Endovascular Thrombectomy Recanalization in Posterior Circulation Arterial Occlusion (ATTRACTION-MINOP)
NCT07594301· Phase 2/3· Source
Not yet recruiting
Denosumab Strategy for Liver Cancer With Bone Metastases
NCT07537972· Phase 2· Source
Not yet recruiting
Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis
NCT07502105· Source
Not yet recruiting
Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
NCT07537959· Source
Recruiting
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
NCT07526493· Phase 1· Source
Recruiting
Human Umbilical Cord Mesenchymal Stem Cell Injection for Diabetic Nephropathy
NCT07822152· Phase 1· Source
Not yet recruiting
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
NCT07486479· Phase 3· Source
Not yet recruiting
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
NCT07448376· Source
Recruiting
Efficacy of Acupuncture-Mesalazine Combination Therapy in Ulcerative Colitis.
NCT07389824· Source
Recruiting
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
NCT07392541· Phase 1/2· Source
Recruiting
Prospective Validation of an AI Model for Predicting Liver Metastasis in Colorectal Cancer
NCT07392567· Source
Recruiting
Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
NCT07402525· Source
Not yet recruiting
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）
NCT07399444· Early phase 1· Source
Not yet recruiting
ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）
NCT07314567· Source
Recruiting
Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment
NCT07587216· Source
Active, not recruiting
Desvenlafaxine for Preventive Treatment of Frequent Migraines
NCT07385755· Source
Recruiting
Construction of AI Model for Precision Imaging Diagnosis of Cranial Diseases
NCT07446842· Source
Not yet recruiting
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
NCT07350070· Phase 2· Source
Not yet recruiting
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
NCT07350824· Source
Recruiting
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
NCT07154082· Phase 2· Source
Recruiting
Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion
NCT07302854· Phase 2/3· Source
Recruiting
A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
NCT07326137· Source
Recruiting
Impact of Emotional Disorders on Response to Immune Checkpoint Inhibitor Therapy in Liver Cancer
NCT07325565· Source
Recruiting
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
NCT07337785· Early phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Liver and biliary tract cancer35 recruiting
Lung cancer16 recruiting
Gastric and esophageal cancer11 recruiting
Pancreatic cancer11 recruiting
Childhood cancers8 recruiting
Colorectal cancer8 recruiting
Stroke8 recruiting
Multiple myeloma7 recruiting
Bladder cancer6 recruiting
Lupus (SLE)6 recruiting
Cervical cancer5 recruiting
Hepatitis B5 recruiting
Multiple sclerosis5 recruiting
Myasthenia gravis5 recruiting
Endometrial cancer4 recruiting
High blood pressure4 recruiting
Ovarian cancer4 recruiting
Type 2 diabetes4 recruiting
Alzheimer disease3 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
Coronary artery disease3 recruiting
Heart failure3 recruiting
Neuromyelitis optica (NMOSD)3 recruiting
Acute lymphoblastic leukaemia2 recruiting
Acute myeloid leukemia2 recruiting
Chronic kidney disease2 recruiting
Crohn's disease2 recruiting
Diffuse large B-cell lymphoma2 recruiting
Fatty liver disease (MASLD/MASH)2 recruiting
Head and neck cancer2 recruiting
Metastatic breast cancer2 recruiting
Obesity2 recruiting
Prostate cancer2 recruiting
Sarcoma2 recruiting
Ulcerative colitis2 recruiting
ALS (motor neurone disease)1 recruiting
Amyloidosis1 recruiting
ANCA-associated vasculitis1 recruiting
Ankylosing spondylitis1 recruiting
Atopic dermatitis (eczema)1 recruiting
Atrial fibrillation1 recruiting
Chronic lymphocytic leukaemia1 recruiting
COPD1 recruiting
Haemophilia1 recruiting
IgA nephropathy1 recruiting
Kidney cancer1 recruiting
Mantle cell lymphoma1 recruiting
Migraine1 recruiting
Myelodysplastic syndromes1 recruiting
Neuroblastoma1 recruiting
Neuroendocrine tumours1 recruiting
Pulmonary arterial hypertension1 recruiting
Systemic sclerosis (scleroderma)1 recruiting
Thyroid cancer1 recruiting
Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

Completed
Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
NCT07705412· Source
Completed
Heparin for RAO Post-Transradial Angiography in AIS
NCT07162064· Phase 3· Source
Completed
Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke
NCT06696820· Phase 2/3· Source
Completed
Correlation Between Body Composition and Pathologic Grade/Prognosis in GEP-NENs: A Retrospective Study
NCT06983106· Source
Completed
HTA of NIVATS Based on RWE
NCT06574295· Source
Completed
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
NCT06498479· Phase 3· Source
Completed
An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
NCT06421740· Source
Completed
Optimizing Early Nutrition Support in Severe Stroke-2
NCT05998902· Phase 3· Source
Completed
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544· Phase 3· Source
Completed
Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant
NCT05978622· Source
Completed
Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma
NCT07030842· Source
Completed
Evaluation of ClearLLab LS Screening Panel
NCT05819762· Source
Completed
Tissue Kallikrein Protect Against Ischemic Stroke
NCT06422572· Source
Completed
Postoperative Pain for Patients After TA-BSM
NCT06433089· Source
Completed
Study of Telitacicept in Generalized Myasthenia Gravis
NCT05737160· Phase 3· Source
Completed
A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
NCT05707351· Phase 3· Source
Completed
A Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal
NCT07637214· Source
Completed
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT05687032· Phase 4· Source
Completed
TESTING -ON Post-Trial ObservatioNal Cohort Study
NCT05434325· Source
Completed
Exercise Prehabilitation for Patients With NSCLC Before Surgery
NCT05608759· Source
Completed
A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT05400369· Phase 4· Source
Completed
Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions
NCT05476978· Source
Completed
A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
NCT05365217· Phase 3· Source
Completed
Anesthetic Management for TA-BSM in HOCM
NCT06397092· Source
Completed
A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC
NCT05236699· Phase 2· Source
Completed
Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma
NCT06776185· Source
Completed
Validation of a Model for Predicting Anastomotic Leakage
NCT05646290· Source
Completed
A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
NCT05053139· Phase 3· Source
Completed
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
NCT05083923· Phase 3· Source
Completed
A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome
NCT06734117· Source
Completed
Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
NCT05003245· Phase 3· Source
Terminated
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
NCT04963270· Phase 3· Source
Completed
Artificial Intelligence Assists Surgeons' Decision Making
NCT04999007· Source
Completed
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835· Phase 3· Source
Terminated
AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer
NCT04993391· Phase 1/2· Source
Terminated
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
NCT04551053· Phase 3· Source
Terminated
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
NCT04735575· Phase 1/2· Source
Completed
Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China
NCT04747496· Source
Terminated
A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NCT04501614· Phase 1/2· Source
Completed
Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
NCT06248554· Source
Completed
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
NCT03776071· Phase 3· Source
Completed
The Number of Mesogastria Containing Metastatic Lymph Nodes Predicts Gastric Cancer Prognosis
NCT06697821· Source
Completed
Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)
NCT04202653· Phase 2· Source
Completed
A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
NCT04846491· Phase 3· Source
Completed
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
NCT03748953· Phase 3· Source
Completed
Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment
NCT04085276· Phase 3· Source
Withdrawn
Efficacy and Safety of Highland Barley Diet on Glucose Variability in Patients With Type 1 Diabetes Mellitus
NCT03766334· Source
Completed
Immunomodulatory Therapy & VSA
NCT06696807· Source
Completed
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
NCT06613633· Source
Completed
The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study
NCT07639294· Source

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Liver and biliary tract cancer180 works · 46 trials
Lung cancer119 works · 32 trials
Prostate cancer51 works · 4 trials
Gastric and esophageal cancer47 works · 17 trials
Ovarian cancer43 works · 7 trials
Bladder cancer37 works · 7 trials
Cervical cancer36 works · 8 trials
Acute myeloid leukemia29 works · 2 trials
Pancreatic cancer28 works · 15 trials
COPD26 works · 2 trials
Glioblastoma24 works · 1 trials
Acute lymphoblastic leukaemia18 works · 4 trials
Hypertrophic cardiomyopathy17 works · 2 trials
Endometriosis14 works · 0 trials
Hepatitis B13 works · 8 trials
IgA nephropathy13 works · 2 trials
Diffuse large B-cell lymphoma13 works · 3 trials
Hodgkin lymphoma12 works · 0 trials
Idiopathic pulmonary fibrosis12 works · 0 trials
Myasthenia gravis10 works · 9 trials
Myelodysplastic syndromes8 works · 1 trials
Neuromyelitis optica (NMOSD)6 works · 3 trials
Sjögren's disease4 works · 0 trials

Institution data: ROR 04xy45965 (CC0-1.0)Updated 10 Nov 2026

Report an error